Mounia Chaoui
Management
Themis
Austria
Biography
Mounia has been a Life Science investor within Ventech (since 2001), Inserm Transfert Initiative (2012) and Atlas Venture (1998 to 1999). She has been on the board of Actogenix (sold to Intrexon), Biovex (sold to Amgen for up to 1 billion USD), Covagen (sold toJ&J), EyeGate (now EYGT), Funxional Therapeutics (sold to Boehringer Ingelheim), Prosonix (sold to Circassia), T Igenix (now EUR:TIG) and SCYNEXIS (SCYX). Besides Themis, Mounia is on the board of Alize Pharma, Didactic, DNA therapeutics, EyeGate, EYETECHCARE, JRI and SEBBIN. Mounia holds a PhD in Biophysics and an Engineering degree from Ecole Centrale Paris.
Research Interest
Clinical research, Clinical sciences, Clinical trials
